Pete Jiro Tanaka, M.D., Ph.D.

The second son of Dr. Shigeru Tanaka.
Born on March 5, 1956 in Japan

Attended Elementary and High School at Saint Mary’s School, a French missionary school, in Tokyo
From 8-11 years old, studied in Madrid, Spain because at that time, Dr. Shigeru Tanaka was the President of Japan-Latino America Medical Association

1982 Graduated at Nihon University School of Medicine
1982-1984 Internship at Keio University Hospital Department of Diagnostic Radiology
1985-1988 Fellowship at Keio University Hospital Department of Diagnostic Radiology
1989-1994 Tokyo Metropolitan General Hospital
1995-1997 Asaka Kosei Hospital, Assistant Director
1998-present Akasaka International Clinic, Medical Director
2002-present Asaka Kosei Hospital, Chairman of the Board of Directors

Clinical experience with EM-X started in 1996 in collaboration with Dr. Shigeru Tanaka.

2004-2006 Conducted a research on EM-X at the Institute for Advanced Medical Research in Keio University

Presentation
Sunday, September 10th, 2006 / 9:30 – 9:50

EM-X USE BY HUMANS – A CASE STUDY FROM JAPAN

ABSTRACT
The use of EMX in treating humans for a wide range of health conditions was initiated in 1995, through a series of telephone consultations. As the numbers of patients treated through this method exceeded 10,000 in Japan, a survey was initiated in 2004 among a random selection of these patients to evaluate the efficacy of EMX in treating the different diseases. The questions ranged from gender, age, diagnosis, stage of cancer, metastasis, side effects of chemotherapy, allergy, family history of cancer, dosage of EM-X, EM-1 intake, in combination with other treatments, and the subjective reports on patients’ condition after EM-X intake covering 1, 3 and 6 months. A total of 1360 patients were identified, of whom 401 (29.5%) responded. The results highlighted the success and thus today efforts are being made to develop dosage and other clinical approaches to treating different diseases with EMX. The presentation highlights the success achieved and future plans to develop an effective curative program using EMX.

Keywords: Human Health, EMX, Case study, Japan, Dosage development